Cancer Diagnostics
… will work with UK pathology firm LDPath to roll out software for England’s National Health Service in bid to weed out misdiagnoses 0 shares Ibex Medical Analytics is an Israeli maker of AI-based cancer diagnostics software (Courtesy) Ibex Medical Analytics, a maker of cancer diagnostic software, in collaboration with UK’s LDPath, a provider of digital pathology services to England’s National Health Service (NHS), has started rolling out its clinical …
SAN FRANCISCO The global thyroid cancer diagnostics market size is expected to reach USD 3.6 billion by 2027, expanding at a CAGR of 5.5% , according to a new report by Grand View Research, Inc. The growth of the market is attributed to increasing disease prevalence and emergence of novel diagnostic products. Although the cancer is uncommon worldwide, the incidence rate is on the rise-driven by more sensitive and precise …
Cancer Diagnostics Market Outlook, Global Demand and Rising Trends 2016-2026 | 7/1/2020
Health care stakeholders need to invest in value-based care, innovative care delivery models, advanced digital technologies. XploreMR will help you to know declarative, procedural, contextual, and somatic information about the “ Cancer Diagnostics Market ”. It also provides a critical assessment of the performance of emerging and mature markets in a new publication titled “ Cancer Diagnostics Market : Biopsy Test Type Segment Expected to Remain Dominant Throughout the Forecast Period: Global Industry …
LDPath will deploy Ibex’s Galen ™ Prostate, an AI-powered solution to support pathologists in enhancing diagnostic accuracy and efficiency TEL AVIV, Israel and LONDON , June 30, 2020 /PRNewswire/ – Ibex Medical Analytics , the pioneer in artificial intelligence (AI)-powered cancer diagnostics and LDPath, a leading provider of digital pathology services to the NHS, today announced the UK’s first rollout of clinical grade AI applications for cancer detection in pathology . In recent …
Contact Us Global Distribution Newswire Services Regulatory Filings Media Partners The Global Cancer Diagnostics Market is expected to grow from USD 140,325.96 Million in 2019 to USD 221,237.88 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.88% Market Segmentation & Coverage: This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets: June 30 …
UK rolls out AI-based cancer detection for NHS patients | Healthcare IT News | 6/30/2020
Leader in AI-powered cancer diagnostics , Ibex Medical Analytics and provider of digital pathology services in the NHS, LDPath, have announced the UK’s first rollout of clinical grade AI application for cancer detection in pathology. This platform will support pathologists in enhancing diagnostic accuracy and efficiency. WHY IT MATTERS Over the years, a global increase in cancer cases has coincided with a decline in the number of pathologists around the …
Deep Learning Technique Could Improve Cancer Diagnostics | HealthIT Analytics | 6/30/2020
A new two-step technique to train deep learning algorithms could enhance researchers’ understanding of cancer diagnostics and biology. Source: Thinkstock By June 30, 2020 - A team from the Lawrence J. Ellison Institute for Transformative Medicine of USC have developed a technique to train a deep learning algorithm for improved cancer diagnostics. In a , researchers describe using novel tissue fingerprints of tumors paired with correct diagnoses to facilitate deep learning …
Israeli AI Diagnostics Firm Ibex To Roll Out Cancer Screening For NHS Patients In UK | 6/30/2020
Founded in 2014, Ibex develops clinical-grade, AI-based solutions that help pathologists detect and grade cancer in biopsies. Ibex’s Galen Prostate and Galen Breast are the first AI-powered cancer diagnostics solutions in routine clinical use in pathology, the company says, and are deployed in labs worldwide. These solutions empower pathologists to improve diagnostic accuracy and enable a more efficient workflow, Ibex says. SEE ALSO: Israeli Study Finds Molecule …
Investigating Breast Cancer: The Promise and Potential of Breast Cancer Vaccines | 6/30/2020
… that there have been a lot of advances in nucleic acid sensing and testing that is coming out from the COVID-19 epidemic that I predict and in turn, will end up impacting breast cancer diagnostics and care as we learn better how to sense nucleic acid in this case for corona viral nucleic acid. But I think that many of those systems and approaches are going to start to …
Cergentis Appoints New CEO and Board Members | PR Newswire | 6/29/2020
… of the Board: “A heartfelt gratitude to outgoing CEO Jan Dekker , who laid the foundation for Cergentis to take the next step to accelerate the development and commercialization of its unique TLA technology for cancer diagnostics . We are pleased to welcome Joris as new CEO. Joris has an excellent international track record in the biotech industry. We are also very pleased with the appointment of our new Board members Maja …
… methylation assays have been performed to define the DNA methylation signature of tumour samples [ 18 , 19 ], the ability to study cancers through non-invasive sampling of body fluids is a rapidly advancing development in cancer diagnostics and prognosis. In particular, biomarkers identified in blood hold promise as non-invasive prognostic tools and may potentially be used to direct treatment if shown to be informative proxies for cancer development and prognosis …
Google Alert - stock | 6/28/2020
stock As-it-happens update ⋅ June 28, 2020 NEWS Could Invitae Be a Millionaire-Maker Stock ? Motley Fool Could Invitae Be a Millionaire-Maker Stock ? After a $1.4 billion merger, can Invitae become an industry leader in genetic testing and cancer diagnostics ? Flag as irrelevant Stock market crash: 6 dividend-paying bargains I’m thinking of buying for my ISA Yahoo Finance UK There are many other terrific dividend-paying stocks …
Could Invitae Be a Millionaire-Maker Stock? | 6/28/2020
After a $1.4 billion merger, can Invitae become an industry leader in genetic testing and cancer diagnostics ? (TMFZhiyuanSun) Jun 28, 2020 at 7:17AM In the past three months alone, shares of genetic testing company Invitae ( NYSE:NVTA ) have soared by 90%. In fact, the company’s shares outperformed the S&P 500’s return of 25% by nearly five times during the same period. At this rate, investors may be wondering …
RNA Sequencing as Alternative to Immunohistochemistry in Cancer Diagnostics | 6/27/2020
RNA Sequencing as Alternative to Immunohistochemistry in Cancer Diagnostics Researchers from the Moscow Institute of Physics and Technology have succeeded in using RNA sequencing as an alternative to immunohistochemistry for cancer diagnostics. 1 The conventionally used method for cancer diagnostics relies on immunohistochemical dyeing of tumor tissue sections, which allows the user to detect the presence and measure the concentration of marker proteins characterizing malignant growths. The procedure involves immersing …
… robust seal are some of the key attributes that make these prefilled vials suitable for the safe collection of specimen and their transportation. The role of formalin as tissue fixative drives its use in cancer diagnostics . Their use is gaining traction ambulatory surgical centers that need small biopsies. Growing efforts to constantly bring innovations in product lines are expected to create new avenues in the prefilled formalin vials market. The …
… charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report Related Reports on Healthcare Include: Global Head and Neck Cancer Diagnostics Market – Global head and neck cancer diagnostics market by geography (Asia, Europe, North America, and ROW) and diagnostic methods (biopsy and blood tests, imaging, endoscopy, and dental diagnostics). About Technavio Technavio is a leading …
… robust seal are some of the key attributes that make these prefilled vials suitable for the safe collection of specimen and their transportation. The role of formalin as tissue fixative drives its use in cancer diagnostics . Their use is gaining traction ambulatory surgical centers that need small biopsies. Growing efforts to constantly bring innovations in product lines are expected to create new avenues in the prefilled formalin vials market. The …
… charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report Related Reports on Healthcare Include: Global Head and Neck Cancer Diagnostics Market – Global head and neck cancer diagnostics market by geography (Asia, Europe, North America, and ROW) and diagnostic methods (biopsy and blood tests, imaging, endoscopy, and dental diagnostics). About Technavio Technavio is a leading …
Prof. Richard Mammone, Professor of engineering and business at Rutgers University. | 6/26/2020
Artificial Intelligence, Breast cancer diagnostics , Teleradiology, Social return to technology commercialization Prof. Richard Mammone, a professor of engineering and business at Rutgers University. He is a fellow of the National Academy of Inventors, recipient of the Thomas Edison Patent Award and inductee of the New Jersey Inventors Hall of Fame. He has published over 200 papers and has 30 patents. He was a founding editorial board member of the IEEE …
… 30 and children. Some of the major brain tumors are caused due to atomic bomb exposure, medical exposure, ionizing radiation. These are some of the other factors responsible for the augmentation of the brain cancer diagnostics market. The MRI segment is predicted to dominate the market owing to its characteristics like high accuracy in the brain tumor diagnostics. Additionally, a rising rate of occurrence of brain cancer across the world …
… the stock price touched more than $30, an all-time high for the 10-year-old San Francisco-based genetic information company. ArcherDX has more than 325 unique products and is developing in-vitro cancer diagnostics , with Food and Drug Administration submissions expected later this year, according to an article in FierceBiotech. The company’s Stratafide DX and Personalized Cancer Monitoring efforts have both received breakthrough device designations from the agency …
… impact, such as a system that makes use of topological maps to predict mudflows, facilitating stakeholders’ preemptive response abilities, or a system that detects nodules in thyroids from ultrasound images and assists in potential cancer diagnostics . The knowledge and expertise fostered from these and many other past projects that make use of cutting-edge technologies to solve problems in real-life situations, will be employed to drive this project to …
Study uses RNA sequencing as alternative to immunohistochemistry in cancer diagnostics | 6/25/2020
Study uses RNA sequencing as alternative to immunohistochemistry in cancer diagnostics Study uses RNA sequencing as alternative to immunohistochemistry in cancer diagnostics Share Credit: Daria Sokol/MIPT Press Office For the first time, researchers from the Moscow Institute of Physics and Technology and their colleagues have succeeded in using RNA sequencing as an alternative to immunohistochemistry for cancer diagnostics. Their study was published in Biomedicines . The conventionally used method for …
For the first time, researchers from the Moscow Institute of Physics and Technology and their colleagues have succeeded in using RNA sequencing as an alternative to immunohistochemistry for cancer diagnostics. Their study was published in Biomedicines . The conventionally used method for cancer diagnostics relies on immunohistochemical dyeing of tumor tissue sections. It allows to detect the presence and measure the concentration of marker proteins characterizing malignant growths. The procedure involves …
This report also researches and evaluates the impact of Covid-19 outbreak on the Kidney Cancer Diagnostics industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Kidney Cancer Diagnostics and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). Global Info Research offers a latest published report on Kidney Cancer Diagnostics Market Analysis and Forecast …
Medical Analytics
LDPath will deploy Ibex’s Galen ™ Prostate, an AI-powered solution to support pathologists in enhancing diagnostic accuracy and efficiency TEL AVIV, Israel and LONDON , June 30, 2020 /PRNewswire/ – Ibex Medical Analytics , the pioneer in artificial intelligence (AI)-powered cancer diagnostics and LDPath, a leading provider of digital pathology services to the NHS, today announced the UK’s first rollout of clinical grade AI applications for cancer detection in pathology . In recent …
Biotech
Cergentis Appoints New CEO and Board Members | PR Newswire | 6/29/2020
… today announced the appointment of Joris Schuurmans as CEO and Dirk Pollet and Maja Sanders as Supervisory Board members. Novalis Biotech Incubation will invest in Cergentis’ growth potential. Incoming CEO Joris Schuurmans has extensive experience … the development and commercialization of its unique TLA technology for cancer diagnostics. We are pleased to welcome Joris as new CEO. Joris has an excellent international track record in the biotech industry. We are also …
COVID-19
… USD 585.17 million as per Technavio. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Request for Technavio’s latest directly and indirectly impacted market reports. Market estimates … report Related Reports on Healthcare Include: Global Head and Neck Cancer Diagnostics Market – Global head and neck cancer diagnostics market by geography (Asia, Europe, North America, and ROW) and diagnostic methods (biopsy and blood tests …
Precision Medicine
June 22, 2020 09:00 ET Source: SEngine Precision Medicine SEATTLE, SEngine Precision Medicine , a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor-based organoids, today presents data on the predictive value of the PARIS® Test in its poster, “Organoid-based functional test to predict personalized treatment in cholangiocarcinoma” (poster board 818), during the 2020 AACR Virtual Meeting being held June 22 …
American Association for Cancer Research
GARDEN GROVE, Calif. , June 22, PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific’s liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity. Early-stage cancer diagnostics and cancer screening applications are limited …
American Academy of Dermatology
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Apr 29, 2020– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of development and validation data … Squamous Cell Carcinoma,” was published in the Journal of the American Academy of Dermatology (JAAD). The study results demonstrate that DecisionDx-SCC is an independent predictor of metastatic risk that can complement current cancer risk …
Food and Drug Administration
Jonathan Shieber @jshieber / 20 hours Personal Genome Diagnostics, the venture-backed developer of a novel diagnostic kit for genomic profiling of different cancers in lab settings, has received clearance from the U.S. Food and Drug Administration for its PGDx elio tissue complete test. The test’s approval is another step forward for precision therapies that rely on an understanding of the unique genomic profile of an individual patient’s tumor, according to …
Personal Genome Diagnostics
Jonathan Shieber @jshieber / 20 hours Personal Genome Diagnostics, the venture-backed developer of a novel diagnostic kit for genomic profiling of different cancers in lab settings, has received clearance from the U.S. Food and Drug Administration for its PGDx elio tissue complete test. The test’s approval is another step forward for precision therapies that rely on an understanding of the unique genomic profile of an individual patient’s tumor, according to …
Yale University School of Medicine
… board: Amir A. Jazaeri , M.D., from the University of Texas MD Anderson Cancer Center and Abhijit Patel , M.D., Ph.D., from Yale University School of Medicine . These two new advisors join George M. Church , Ph.D., and … is working to develop and clinically validate noninvasive DNA-based cancer diagnostics, with a particular focus on assessment of therapeutic efficacy and early cancer detection. He has many publications in top journals including Nature , JAMA …
Rice University
… cancer diagnostics, with a particular focus on assessment of therapeutic efficacy and early cancer detection. He has many publications in top journals including Nature , JAMA and Cancer Research . “I was truly impressed by the Blocker Displacement Amplification (BDA) technology when it was first developed at Rice University. I participated in the first set of clinical sample validation studies using BDA, and the results showed excellent concordance with NGS data,” says …
National Institutes of Health
Genomics Industry Review 2015-2019 and Opportunity Outlook 2020-2030 | PR Newswire | 4/17/2020
… and private institutions. For instance, in 2018, in the U.S, The All of Us Research Program, a part of the National Institutes of Health, gave funds of $28.6 million for establishing three genome centers in … Technologies, Inc., a USA -based biotech company, specialized in developing cancer diagnostics tools launched a CAR-T characterization panel, a new gene expression panel for the molecular characterization of CAR-T cells in research, development …
Genomics
LONDON Companies in the global genomics are investing in new product launches to increase their revenue and expand their consumer base, and also for gaining a competitive edge over their rivals. For instance, in 2018, NanoString Technologies, Inc., a USA -based biotech company specialized in developing cancer diagnostics tools, launched a CAR-T characterization panel, which is a new gene expression panel for the molecular characterization of CAR-T cells …
University of Texas Health Science Center
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Mar 26, 2020– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a multicenter, prospective study … Ophthalmology, Weill Cornell Medical College/Houston Methodist Hospital and the University of Texas Health Science Center at Houston, and Retina Consultants of Houston. “DecisionDx-UM stratifies patients, based on tumor biology, into high- and low …
Molecular Diagnostics
Molecular-based Cancer Diagnostic Market Reaches $1.6 Billion | PRWeb | 2/19/2020
Molecular-based Cancer Diagnostic Market Reaches $1.6 Billion Share Article Healthcare publisher, Kalorama Information, shares details of its latest report on Molecular Cancer Diagnostics. ARLINGTON, Va. Cancer diagnostics is a highly dynamic field that consists of various types of platforms. Molecular diagnostics platforms are increasingly becoming popular as they enable accurate diagnosis as well as prognosis evaluation, which are important for treatment decisions. In 2019, the market for molecular cancer …
Diagnostic Tests
… diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report. This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug class (HER2 inhibitors …
Cancer Biomarkers
… Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics) National Academy of Sciences (NAS) [US] Nephromics Novartis Novartis Molecular Diagnostics (part of Novartis) NovioGendix Oncoimmune Oncomedics OpGen OPKO Health Orion Genomics Oxford Cancer Biomarkers Oxford Gene Technology Pacific Biomarkers Pacific Biosciences Panomics (now part of Affymetrix) Parexel Patheon Pathwork Diagnostics Personal Genome Diagnostics Pfizer Pierre Fabre PLUS Diagnostics PMDA Power3 Medical Products PPD Predictive Biosciences Prometheus Laboratories ProtagenAG Proteome …
Clinical Research
… Cole , PhD The Future of Consumer Genomics, Yaniv Ehrlich , Ph Re-synthesizing Biology, Steven Benner , PhD Hot Topics: Liquid Biopsy Cancer Diagnostics and Application of Immunogenomics to Cancer Therapy Defining Best Clinical Practices in Genomic … of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and …
Companion Diagnostics
… cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug class (HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors and hormone receptors), geographic market segmentation of the overall market and global market share by company with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for the year 2018 (the base year), 2019 and a forecast for 2024. Report …
Cancer Therapy
… Cancer Diagnostics and Application of Immunogenomics to Cancer Therapy Defining Best Clinical Practices in Genomic Testing of Healthy Individuals Cutting Edge Scientific Concurrent Sessions: The Evolving Landscape of Delivering Genetics Services: Tangled Policies and Financial Considerations The Genetics Hotline: Responsibility and Liability When Handling Unsolicited Patient Communications Artificial Intelligence and Genomics: Powerful Tools in Pre- and Postnatal Decision Making The Gene Pool: Sharing Our Best Ideas for the Genetics Workforce …
Medical Research
TEL AVIV, Israel , Dec. 4, Ibex Medical Analytics, the pioneer in artificial intelligence (AI)-powered cancer diagnostics, and the KSM Research and Innovation Institute at Maccabi Healthcare Services, announce the deployment of the Ibex Second … analytics. We aim to increase the amount and quality of medical research being performed at any given moment in Israel and worldwide and partner with the most advanced AI companies to develop innovative, predictive and …
Centers for Medicare and Medicaid Services
… List of Organizations Mentioned in the Report American College of Cardiology Foundation (ACCF) American Heart Association (AHA) Association for Molecular Pathology (AMP) [US] British Heart Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European Medicines Agency) ETH Zurich European Commission European Federation of Pharmaceutical Industries and …
Medical Imaging
… Digital Pathology Solution News provided by Sectra, Inc Dec 02, 2019, 11:00 ET SHELTON, Connecticut , Dec. 2, 2019 /PRNewswire/ – International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Leica Biosystems announce collaboration … www.sectra.com/medical/ . About Leica Biosystems Leica Biosystems ( LeicaBiosystems.com ) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, Leica Biosystems is …
Digital Pathology
Sectra and Leica Biosystems Partner to Pursue FDA Clearance for an Integrated Clinical Digital Pathology Solution News provided by Sectra, Inc Dec 02, 2019, 11:00 ET SHELTON, Connecticut , Dec. 2, 2019 /PRNewswire/ – International medical imaging … www.sectra.com/medical/ . About Leica Biosystems Leica Biosystems ( LeicaBiosystems.com ) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, Leica Biosystems is …
Enterprise Imaging
… pathology industry and a huge step forward in clinical usability.” The Sectra digital pathology software solution, a component of the enterprise imaging offering, will facilitate streamlined image access, review, and diagnosis, as well as deep … www.sectra.com/medical/ . About Leica Biosystems Leica Biosystems ( LeicaBiosystems.com ) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, Leica Biosystems is …
PACS
IBM Focuses on Expanding its Watson Health Imaging Business | Zacks | 12/2/2019
… be showcasing solutions across AI and Machine Learning, Enterprise Imaging, Vendor Neutral Archive, Image Viewing and Sharing as well as PACS.We note that on Oct 30, 2019, Clinical Review 3.0 was launched in the U.K … the development of an AI software solution pertaining to prostate cancer diagnostics and monitoring. The solution entails the use of MR imaging. This deal marks an extension between IBM Watson Health and Guerbet’s earlier collaboration …
Qiagen
… rising demand for Illumina’s systems as it uses the SBS technology. Major players operating in the global next-generation sequencing market include Illumina, Inc., Thermo Fisher Scientific, Inc, BGI Group, Agilent Technologies, Inc., Qiagen N.V., Hoffmann-La Roche AG, 10x Genomics, Oxford Nanopore Technologies, Takara Bio and others. Years considered for this report: Historical Years: 2015-2018 …
Ibex Medical Analytics
LDPath will deploy Ibex’s Galen ™ Prostate, an AI-powered solution to support pathologists in enhancing diagnostic accuracy and efficiency TEL AVIV, Israel and LONDON , June 30, 2020 /PRNewswire/ – Ibex Medical Analytics , the pioneer in artificial intelligence (AI)-powered cancer diagnostics and LDPath, a leading provider of digital pathology services to the NHS, today announced the UK’s first rollout of clinical grade AI applications for cancer detection in pathology . In recent …
Siemens
LONDON- Technavio has been monitoring the head and neck cancer diagnostics market and it is poised to grow by USD 3.41 billion during 2020-2024, progressing at a CAGR of almost 12% during the forecast period … SE & Co. KG, Koninklijke Philips NV, Neusoft Corp., Olympus Corp., Siemens AG, and Varian Medical Systems Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus …
Illumina
Foundation Medicine acquires liquid biopsy developer Lexent Bio | FierceBiotech | 6/15/2020
… cancer diagnostics. Financial terms of the deal were not disclosed. According to Foundation, Lexent’s tech complements the company’s existing research efforts in tracking disease progression and guiding treatment decisions through genomics. Lexent had been developing an in vitro diagnostic for monitoring minimal residual disease linked to certain solid tumors and measuring a patient’s response to therapy. In November 2019 , the San Francisco-based company inked a development deal with Illumina …
Abbott Laboratories
… include pre- and post-COVID-19 impact on the Cervical Cancer Diagnostic Testing Market Download free sample report The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Becton, Dickinson and Co., bioMérieux SA, Bio-Rad Laboratories Inc., Cardinal Health Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN NV, Quest Diagnostics Inc., and Siemens Healthineers AG are some of the major market …
Thermo Fisher
… a China-based precision oncology company that covers full-cycle cancer care, has entered into a strategic partnership agreement with Thermo Fisher Scientific (“Thermo Fisher”). With plans to build on the sequencer Genetron S5 (Registration … research. “Genetron Health is committed to leading and empowering the cancer diagnostics and treatment industry,” said Wang Sizhen, Co-Founder and CEO of Genetron Health. “We have been working with Thermo Fisher, one of our …
Thermo Fisher Scientific
… a China-based precision oncology company that covers full-cycle cancer care, has entered into a strategic partnership agreement with Thermo Fisher Scientific (“Thermo Fisher”). With plans to build on the sequencer Genetron S5 (Registration … research. “Genetron Health is committed to leading and empowering the cancer diagnostics and treatment industry,” said Wang Sizhen, Co-Founder and CEO of Genetron Health. “We have been working with Thermo Fisher, one of our …
National Medical Products Administration
… microorganism testing, and other independent clinical lab testing and scientific research. “Genetron Health is committed to leading and empowering the cancer diagnostics and treatment industry,” said Wang Sizhen, Co-Founder and CEO of Genetron Health … to improve public health throughout China.” Genetron Health has received National Medical Products Administration (NMPA) approval for clinical application of seven IVD products, which cover three major technology platforms: the NGS, dPCR and qPCR. The …
Amazon Web Services
… Amazon Web Services its preferred cloud provider to increase its analytics and machine learning services and enhance clinicians’ use of the EHR. Aug. 7, 2019: Amazon Web Services partners with the Pittsburgh Data Alliance in a machine learning research sponsorship focused on advancing innovation in cancer diagnostics, precision medicine, voice-enabled technologies and medical imaging. Aug. 7, 2019: UCHealth launches a skill for the Amazon Echo that allows users to …
Amazon Health
In the past year, Amazon has grown its healthcare presence with the launch of its virtual medical clinic Amazon Care as well as partnerships with health IT companies including Cerner and Change Healthcare. Here’s a … a machine learning research sponsorship focused on advancing innovation in cancer diagnostics, precision medicine, voice-enabled technologies and medical imaging. Aug. 7, 2019: UCHealth launches a skill for the Amazon Echo that allows users to …
Bristol-Myers
DUBLIN The “Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020” report has been added to ResearchAndMarkets.com’s offering. This report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by … Imaging Breath Diagnostics Brigham and Women’s Hospital Bristol- Myers Squibb Bristol-Myers Squibb Pakistan Broad Institute Bruker Buck Institute for Age Research Burning Rock Butantan Institute C4 Imaging Caliber Imaging & Diagnostics Cambridge Epigenetix CANbridge Life …
Bristol-Myers Squibb
DUBLIN The “Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020” report has been added to ResearchAndMarkets.com’s offering. This report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by … Imaging Breath Diagnostics Brigham and Women’s Hospital Bristol- Myers Squibb Bristol-Myers Squibb Pakistan Broad Institute Bruker Buck Institute for Age Research Burning Rock Butantan Institute C4 Imaging Caliber Imaging & Diagnostics Cambridge Epigenetix CANbridge Life …
Celgene
DUBLIN The “Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020” report has been added to ResearchAndMarkets.com’s offering. This report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by … Reserve University Catholic University Leuven CBD Vida CBLPath CDx Diagnostics Celgene Cellgen Diagnostics CellSight Technologies Cell Signaling Technology Celsee Celsion Celsius Therapeutics Celtic Biotech Center for Connected Health Centogene Centre for Imaging Technology Commercialization Centre …
Leica Biosystems
VISTA, Calif. Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received additional notification from the U.S. Food & Drug Administration (FDA) about its intention to exercise enforcement discretion when the Aperio … barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and …
Roche Diagnostics
… the efficiency and scale they need to meet the demands of high-volume cervical screening programs,” said Thomas Schinecker, CEO Roche Diagnostics. “This is critical as most healthcare providers in the US have adopted HPV … the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and …
Genomic Health
Genomics Industry Review 2015-2019 and Opportunity Outlook 2020-2030 | PR Newswire | 4/17/2020
… competitive edge over their rivals. For instance, in 2018, NanoString Technologies, Inc., a USA -based biotech company, specialized in developing cancer diagnostics tools launched a CAR-T characterization panel, a new gene expression panel for … screening for early detection and prevention of colorectal cancer, acquired Genomic Health Inc. for $2.8 billion in cash. The acquisition is expected to help Exact Sciences Corp. to broaden its offering of cancer tests and …
Exact Sciences
Genomics Industry Review 2015-2019 and Opportunity Outlook 2020-2030 | PR Newswire | 4/17/2020
… cancer diagnostics tools launched a CAR-T characterization panel, a new gene expression panel for the molecular characterization of CAR-T cells in research, development, and manufacturing. The panel was developed in partnership with eight leading CAR-T therapy centers and helps in ease of workflow and aims to advance the field of CAR-T therapy. In November 2019 , Exact Sciences Corp., a USA -based molecular diagnostics company specialized in …
Johnson & Johnson
… competitive edge over their rivals. For instance, in 2018, NanoString Technologies, Inc., a USA -based biotech company specialized in developing cancer diagnostics tools, launched a CAR-T characterization panel, which is a new gene expression … the genomics market include 10X Genomics, Qiagen NV, Fluidigm Corporation, Johnson & Johnson Private Limited, Zephyrus Biosciences Inc., Illumina, Inc., Affymetrix, Angle PLC, Denovo Sciences Inc., Diagnologix llc, DNA Electronics Ltd, Enumeral, Epic Sciences, Kellbenx Inc …
IBM Watson Health
Biovica Strengthens its Commercial Leadership | PR Newswire | 3/25/2020
UPPSALA, Sweden , March 25, Biovica, active in cancer diagnostics, today announced that Robert Dann is joining the organization as SVP Marketing and US Business and will be part of the management team. The appointment marks … analytics. He previously led life sciences and oncology marketing at IBM Watson Health. He also served in roles leading strategic marketing and oncology marketing at GE Healthcare. Earlier in his career, among other roles, Robert …
IBM Watson
Biovica Strengthens its Commercial Leadership | PR Newswire | 3/25/2020
UPPSALA, Sweden , March 25, Biovica, active in cancer diagnostics, today announced that Robert Dann is joining the organization as SVP Marketing and US Business and will be part of the management team. The appointment marks … analytics. He previously led life sciences and oncology marketing at IBM Watson Health. He also served in roles leading strategic marketing and oncology marketing at GE Healthcare. Earlier in his career, among other roles, Robert …
Quest Diagnostics
DUBLIN- The “Lung Cancer Diagnostics - Market Analysis, Trends, and Forecasts” report has been added to ResearchAndMarkets.com’s offering. The Lung Cancer Diagnostics market worldwide is projected to grow by US$1.3 Billion, driven by a compounded … NanoString Technologies NeoGenomics Laboratories Inc. PlexBio Co., Ltd. QIAGEN GmbH Quest Diagnostics Thermo Fisher Scientific Inc. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Early Detection of Lung Cancer …
Myriad Genetics
DUBLIN- The “Lung Cancer Diagnostics - Market Analysis, Trends, and Forecasts” report has been added to ResearchAndMarkets.com’s offering. The Lung Cancer Diagnostics market worldwide is projected to grow by US$1.3 Billion, driven by a compounded … Dr Lal PathLabs F. Hoffmann-La Roche AG Illumina Inc. Myriad Genetics Inc. NanoString Technologies NeoGenomics Laboratories Inc. PlexBio Co., Ltd. QIAGEN GmbH Quest Diagnostics Thermo Fisher Scientific Inc. Key Topics Covered: I. INTRODUCTION, METHODOLOGY …
Guardant Health
Global Lung Cancer Diagnostics Industry | PR Newswire | 12/18/2019
NEW YORK , Dec. 18, Lung Cancer Diagnostics market worldwide is projected to grow by US$1 . 3 Billion, driven by a compounded growth of 8%. Imaging Tests, one of the segments analyzed and sized in … ROCHE DIAGNOSTICS 22. FULGENT GENETICS 23. GENEKOR MEDICAL SA 24. GUARDANT HEALTH, INC. 25. ILLUMINA, INC. 26. IMMUNOVIA AB 27. INIVATA LTD. 28. LUCENCE DIAGNOSTICS PTE LTD. 29. MEDGENOME LABS LTD. 30. MYRIAD GENETICS, INC …
Pfizer
… analysis, patent analysis and reimbursement scenarios are some additions to the current report. This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug … Inc., Abbott Laboratories, Dako, Eli Lilly and Co., Nanostring Technologies, Pfizer Inc., Puma Biotechnology Inc., and Sanofi S.A. Key Topics Covered: Chapter 1 Introduction Study Goals and Objectives Reasons for Doing This Study Scope of …
AbbVie
… analysis, patent analysis and reimbursement scenarios are some additions to the current report. This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug … patent analysis Profile descriptions of the key market leaders, including AbbVie Inc., Abbott Laboratories, Dako, Eli Lilly and Co., Nanostring Technologies, Pfizer Inc., Puma Biotechnology Inc., and Sanofi S.A. Key Topics Covered: Chapter 1 Introduction …
Boulder Ventures
… Biomarkers 15.4. miRNA Biomarkers in Oncological Disorders 15.4.1. Importance of Early Cancer Detection 15.4.2. Cancer Screening and Diagnosis 15.4.3. Conventional Cancer Diagnostics 15.4.4. Need for Non-Invasive Approaches 15.4.5. Key Indications 15.4.5.1. Prostate Cancer 15.4.5.2 … BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad Institute Broadview Ventures Calimmune CAMP4 Therapeutics C-Bridge Capital Cell Signaling Technology Cellecta Celsion Cenix BioScience …
… Biomarkers 15.4. miRNA Biomarkers in Oncological Disorders 15.4.1. Importance of Early Cancer Detection 15.4.2. Cancer Screening and Diagnosis 15.4.3. Conventional Cancer Diagnostics 15.4.4. Need for Non-Invasive Approaches 15.4.5. Key Indications 15.4.5.1. Prostate Cancer 15.4.5.2 … BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad Institute Broadview Ventures Calimmune CAMP4 Therapeutics C-Bridge Capital Cell Signaling Technology Cellecta Celsion Cenix BioScience …
TPG Biotech
… Biomarkers 15.4. miRNA Biomarkers in Oncological Disorders 15.4.1. Importance of Early Cancer Detection 15.4.2. Cancer Screening and Diagnosis 15.4.3. Conventional Cancer Diagnostics 15.4.4. Need for Non-Invasive Approaches 15.4.5. Key Indications 15.4.5.1. Prostate Cancer 15.4.5.2 … Project The Medicines Company Tha Open Innovation Thermo Fisher Scientific TPG Biotech Transgene Biotek transOMIC technologies Transplant Genomics Stanford University University of California University of Pennsylvania University of Texas University of Virginia School of Medicine …
… Biomarkers 15.4. miRNA Biomarkers in Oncological Disorders 15.4.1. Importance of Early Cancer Detection 15.4.2. Cancer Screening and Diagnosis 15.4.3. Conventional Cancer Diagnostics 15.4.4. Need for Non-Invasive Approaches 15.4.5. Key Indications 15.4.5.1. Prostate Cancer 15.4.5.2 … Project The Medicines Company Tha Open Innovation Thermo Fisher Scientific TPG Biotech Transgene Biotek transOMIC technologies Transplant Genomics Stanford University University of California University of Pennsylvania University of Texas University of Virginia School of Medicine …
Goldman Sachs
… Biomarkers 15.4. miRNA Biomarkers in Oncological Disorders 15.4.1. Importance of Early Cancer Detection 15.4.2. Cancer Screening and Diagnosis 15.4.3. Conventional Cancer Diagnostics 15.4.4. Need for Non-Invasive Approaches 15.4.5. Key Indications 15.4.5.1. Prostate Cancer 15.4.5.2 … Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology Guang’anmen Hospital of China Academy of Chinese Medical Sciences Harvard University Helmholtz Zentrum Mnchen Hercules Capital Histalim HuaKong Equity Investment …
… Biomarkers 15.4. miRNA Biomarkers in Oncological Disorders 15.4.1. Importance of Early Cancer Detection 15.4.2. Cancer Screening and Diagnosis 15.4.3. Conventional Cancer Diagnostics 15.4.4. Need for Non-Invasive Approaches 15.4.5. Key Indications 15.4.5.1. Prostate Cancer 15.4.5.2 … Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology Guang’anmen Hospital of China Academy of Chinese Medical Sciences Harvard University Helmholtz Zentrum Mnchen Hercules Capital Histalim HuaKong Equity Investment …
Health Catalyst Capital
… 27 million Series B funding round, which includes new investors ATW Partners and SJF Ventures along with existing investors of Health Catalyst Capital, Inova Health Systems and ARUP Laboratories. “Advancements in the ability to harness … Washington University in St. Louis , PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories and patients worldwide. “We are impressed by the progress PierianDx is making in …
St. Louis-Based Genomics Company, PierianDx, Raises a Big Series B Round | 10/30/2019
… million from ATW Partners and SJF Ventures. In addition to these funders, other existing investors participated in the round, including Health Catalyst Capital, Inova… Tom Chapman October 30, 2019 Featured , Investment , Investments & Funding , St. Louis … by Rakesh Nagarajan (pictured), the company is focused on improving cancer diagnostics and making targeted therapies to treat diseases more accessible to healthcare systems, laboratories, and other health care facilities. By providing this ability to …
SJF Ventures
… The transaction includes RTI’s participation in a $27 million Series B funding round, which includes new investors ATW Partners and SJF Ventures along with existing investors of Health Catalyst Capital, Inova Health Systems and ARUP … Washington University in St. Louis , PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories and patients worldwide. “We are impressed by the progress PierianDx is making in …
St. Louis-Based Genomics Company, PierianDx, Raises a Big Series B Round | 10/30/2019
… a clinical genomic informatics company. This week the company announced that it has raised $27 million from ATW Partners and SJF Ventures. In addition to these funders, other existing investors participated in the round, including … by Rakesh Nagarajan (pictured), the company is focused on improving cancer diagnostics and making targeted therapies to treat diseases more accessible to healthcare systems, laboratories, and other health care facilities. By providing this ability to …
William Blair
Exact Sciences Corp (EXAS) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019
… 45 through 49 and new data for Cologuard 2.0 and our liver cancer test.Exact Sciences is positioned to be the cancer diagnostics leader for years to come. The strong foundation we’ve built for Cologuard and … first question comes from the line of Brian Weinstein with William Blair. Brian Weinstein – William Blair & Company L.L.C. – Analyst Hey, guys. Thanks for taking the questions. Wanted to start out just on a broad question …
… Jeff Elliott - CFO Mark Stenhouse - President of Cologuard Conference Call Participants Patrick Donnelly - Goldman Sachs Brandon Couillard - Jefferies Brian Weinstein - William Blair Doug Schenkel - Cowen & Company Catherine Schulte - Robert W. Baird Dan Brennan - UBS Puneet … approval pathway. Our third priority is advancing our blood-based cancer diagnostics program. The strong foundation we’ve built for Cologuard, and it’s commercial momentum positions Cologuard to lead this field. Though our long-term collaboration …
NCI
… achieving the most benefit to the patient. In funding early-stage, high-growth Massachusetts companies, the START program leverages vetted commercial stage technologies developed under SBIR (Small Business Innovation Research) grants from federal agencies, including the NIH/NCI. Since the program’s founding in 2012, START has provided $21.1 million in non-dilutive investment funding to 85 SBIR supported companies, and helped the winners raise additional capital of over $1 billion …
… cause of death from cancer among American Indian/Alaska Native women. According to the estimates of the National Cancer Institute (NCI), 246,660 new cases and 40,450 deaths were registered due to breast cancer in 2016 … this age group represent a huge unmet need for breast cancer diagnostics. As the number of incident and mortality cases are increasing, demand for mammography is also expected to increase. This remains a major driver …
Safeguard Scientifics
… Safeguard Scientifics, Inc., where he led the Deal/investment team. He was also CEO of Touchpoint Solutions and is a former board member of Intralinks, where he chaired the audit committee. The company was acquired by TA & Associates. Jim was also Chairman of the Board for five years at Clarient, a cancer diagnostics company, when it was acquired by GE Healthcare in December 2010. In addition, Jim was Chairman of …
DUBLIN , October The “Pancreatic Cancer Diagnostics Using Artificial Intelligence for Hospitals: Market Shares, Strategies, and Forecasts, Worldwide 2017 - 2023” report from Wintergreen Research, Inc has been added to Research and Markets’ offering. Hospital artificial intelligence … Electric (GE) 5.3 IBM 5.4 Prognos 5.5 Quest Diagnostics 5.6 Safeguard Scientifics Announces Second Quarter 2017 Financial Results 6. Research Methodology Companies Mentioned Alphabet Atomwise BenevolentAI Berg Drug Discovery Artificial Intelligence Exscientia General Electric GlaxoSmithKline …
Medical Center
VUNO Med® LungCT AI™ Receives MFDS Regulatory Approval | PR Newswire | 4/29/2020
… AI™ is the first medical AI solution to receive MFDS regulatory approval based on multi-center clinical trials carried out by three major hospitals, Kangbuk Samsung Hospital, the National Cancer Center, and Asan Medical Center . According to the results, this solution demonstrated high detection levels with a low false positive rate, proving its high effectiveness. It is the first Korean computer aided detection software (CADe) that detects lung nodules based …
MD Anderson Cancer Center
… of a malignancy. The technology uses flow cytometry of white blood cells and AI to identify tumor-bearing patients. The journal article, co-authored by Anixa with collaborators from the Wistar Institute, the MD Anderson Cancer Center at Cooper and the Cooper Medical School of Rowan University and New Jersey Urology, LLC, highlights study data demonstrating Cchek’s™ ability to distinguish healthy men from high-risk prostate cancer patients with a …
University of Texas MD Anderson Cancer Center
… startup, announced the addition of two world-renowned oncologists to their clinical advisory board: Amir A. Jazaeri , M.D., from the University of Texas MD Anderson Cancer Center and Abhijit Patel , M.D., Ph.D., from Yale University … is working to develop and clinically validate noninvasive DNA-based cancer diagnostics, with a particular focus on assessment of therapeutic efficacy and early cancer detection. He has many publications in top journals including Nature , JAMA …
Harvard Medical School
… University School of Medicine . These two new advisors join George M. Church , Ph.D., and David R. Walt , Ph.D., both from Harvard Medical School , on the NuProbe clinical advisory board, to advise on the product strategy … is working to develop and clinically validate noninvasive DNA-based cancer diagnostics, with a particular focus on assessment of therapeutic efficacy and early cancer detection. He has many publications in top journals including Nature , JAMA …
Moffitt Cancer Center
… Moffitt Cancer Center. Dr. Klein received his undergraduate and medical degrees from Case Western Reserve University and completed post-graduate medical education at Yale University School of Medicine and the Mayo Clinic. In addition, he has a law degree from Yale Law School. “I am thrilled to be joining OmniSeq at an exciting time for cancer diagnostics and precision medicine at a pivotal juncture for the company,” said Dr. Klein …
Methodist Hospital
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Mar 26, 2020– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a multicenter, prospective study … Associate Professor of Clinical Ophthalmology, Weill Cornell Medical College/Houston Methodist Hospital and the University of Texas Health Science Center at Houston, and Retina Consultants of Houston. “DecisionDx-UM stratifies patients, based on tumor biology …
Inova Health System
… B funding round, which includes new investors ATW Partners and SJF Ventures along with existing investors of Health Catalyst Capital, Inova Health Systems and ARUP Laboratories. “Advancements in the ability to harness knowledge from genomics … Washington University in St. Louis , PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories and patients worldwide. “We are impressed by the progress PierianDx is making in …
Memorial Sloan Kettering Cancer Center
(USA-NY-New York) QA Manager - Pathology | 11/12/2019
… Memorial Sloan Kettering Cancer Center has established the standard for what’s possible in cancer diagnostics and care. A dedicated team of more than 650 team members spread across six laboratory services and nine campus locations, all focused on one goal: optimizing patient care by providing a precise and accurate diagnosis utilizing our state-of-the-art clinical laboratories and cutting-edge technologies. Our department consists of subspecialized pathologists, molecular diagnosticians …
Memorial Sloan Kettering
(USA-NY-New York) QA Manager - Pathology | 11/12/2019
Memorial Sloan-Kettering Cancer Center QA Manager - Pathology in New York , New York Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world … Cancer Center has established the standard for what’s possible in cancer diagnostics and care. A dedicated team of more than 650 team members spread across six laboratory services and nine campus locations, all focused on …
Mayo Clinic
Exact Sciences Corp (EXAS) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019
… 45 through 49 and new data for Cologuard 2.0 and our liver cancer test.Exact Sciences is positioned to be the cancer diagnostics leader for years to come. The strong foundation we’ve built for Cologuard and … critical to supporting continued Cologuard adoption over time. Working with Mayo Clinic, we recently initiated Voyage, a 150,000-patient prospective observational study of individuals using Cologuard for routine screening. The seven-year study will follow …
Cleveland Clinic
… of physicians.” Cleveland Diagnostics has concluded two multicenter clinical trials in top U.S. and international hospitals and clinics, led by Cleveland Clinic, in which the diagnostic accuracy of IsoPSA was compared to that of PSA … lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. Its Solvent Interaction Analysis™ (SIA) technology investigates biomarkers at the structural level as opposed to overall concentration, providing better insights as to the …
Cleveland Clinic, Cleveland OH
… of physicians.” Cleveland Diagnostics has concluded two multicenter clinical trials in top U.S. and international hospitals and clinics, led by Cleveland Clinic, in which the diagnostic accuracy of IsoPSA was compared to that of PSA … lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. Its Solvent Interaction Analysis™ (SIA) technology investigates biomarkers at the structural level as opposed to overall concentration, providing better insights as to the …
Good Samaritan Hospital
… years. According to Rakesh Patel , MD, a leading breast cancer radiation oncologist and Medical Director of Breast Cancer Services at Good Samaritan Hospital in Los Gatos, CA , “These findings are important as the patient population … treatment decisions. About PreludeDx PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco , PreludeDx …
Samaritan Hospital
… According to Rakesh Patel , MD, a leading breast cancer radiation oncologist and Medical Director of Breast Cancer Services at Good Samaritan Hospital in Los Gatos, CA , “These findings are important as the patient population (stage … treatment decisions. About PreludeDx PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco , PreludeDx …
Partners HealthCare
Share this article DUBLIN , October 27, 2017 /PRNewswire/ – The “Pancreatic Cancer Diagnostics Using Artificial Intelligence for Hospitals: Market Shares, Strategies, and Forecasts, Worldwide 2017 - 2023” report from Wintergreen Research, Inc has been added to Research … Artificial Intelligence Regional Segments: 3. Hospital Artificial Intelligence Products: 3.1 Partners HealthCare, IBM, and GE Healthcare3.2 IBM Watson3.3 Google’s AI Subsidiary DeepMind is Partnering With Another UK hospital3.4 Prognos 4. Hospital Artificial Intelligence Research and …
Aetna
DUBLIN The “Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020” report has been added to ResearchAndMarkets.com’s offering. This report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by … Advanced Cooling Therapy Advanced Nuclear Medicine Ingredients Aelan Cell Technologies Aetna Agena Bioscience Agendia Agilent Technologies Agios Pharmaceuticals AG Mednet Albert Einstein Healthcare Network Alibaba Health Alliance Global FZ Alliance Global Group Almac Diagnostics Almac …
Exact Sciences Corp (EXAS) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019
… 45 through 49 and new data for Cologuard 2.0 and our liver cancer test.Exact Sciences is positioned to be the cancer diagnostics leader for years to come. The strong foundation we’ve built for Cologuard and … following the American Cancer Society guidelines update last year, including Aetna, CareFirst and Blue Shield of California. This is encouraging progress and our team is engaging with other payers educating their sales force and developing …
Jan Groen
Cergentis Appoints New CEO and Board Members | PR Newswire | 6/29/2020
… Jan Groen , Chairman of the Board: “A heartfelt gratitude to outgoing CEO Jan Dekker , who laid the foundation for Cergentis to take the next step to accelerate the development and commercialization of its unique TLA technology for cancer diagnostics. We are pleased to welcome Joris as new CEO. Joris has an excellent international track record in the biotech industry. We are also very pleased with the appointment of our new …
Fred Hutchinson
June 22, 2020 09:00 ET Source: SEngine Precision Medicine SEATTLE, SEngine Precision Medicine , a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor-based organoids, today presents … Director at SEngine Precision Medicine and full member of the Fred Hutchinson Cancer Research Center, chairs the education session. Chief Executive Officer Dr. Carla Grandori, M.D., Ph.D., presents on the strong predictive value of the …
Laura Wood
DUBLIN The “Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020” report has been added to ResearchAndMarkets.com’s offering. This report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by … focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood , Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 …
Sarah Marsh
England campaign targets seriously ill patients avoiding hospitals | Yahoo News | 4/25/2020
England campaign targets seriously ill patients avoiding hospitals Sarah Marsh and Nazia Parveen April 25, 2020, 7:45 a.m. UTC Photograph: Edward Moss/Alamy Stock Photo A government campaign has been launched to encourage people seriously … concerned to see GP referrals for two-week target turnaround cancer diagnostics drop from 500 a week to 105, NHS Providers reported. Heart attacks and strokes The latest Public Health England data, for 13-19 April …
Carl Zeiss
… competitive edge over their rivals. For instance, in 2018, NanoString Technologies, Inc., a USA -based biotech company specialized in developing cancer diagnostics tools, launched a CAR-T characterization panel, which is a new gene expression … Fisher Scientific Inc., CellBio, Beckman Coulter , Becton Dickinson , Bio-Rad, Carl Zeiss Microscopy, Cell Microsystems, Cellsee Diagnostics, CellSorter, Cytena, CytoTrack, Dolomite Bio, Agilent Technologies Inc., and Fluxion Biosciences. Read More On The Business Research Company’s …
Derek Maetzold
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Apr 6, 2020– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020, at 3:30 p.m. Eastern time. A live audio webcast of the company’s presentation will …
Colin White
… customers to choose their preferred workflow solutions. “This is an important step towards improving patient care with digital technology,” says Colin White , Global Vice President of Leica Biosystems Advanced Staining & Imaging Business. “We look forward … www.sectra.com/medical/ . About Leica Biosystems Leica Biosystems ( LeicaBiosystems.com ) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, Leica Biosystems is …
Torbjörn Kronander
… to deliver a clinical solution to meet the needs of the truly integrated digital hospitals of today and tomorrow,” says Torbjörn Kronander, Founder & CEO of Sectra. “This is an exciting and important advancement for the … www.sectra.com/medical/ . About Leica Biosystems Leica Biosystems ( LeicaBiosystems.com ) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, Leica Biosystems is …
Dennis Johnson
… to empower HMH to assist care givers in their treatment of patients through the use of this revolutionary platform,” said Dennis Johnson , HMH president and CEO. “We look forward to our ongoing collaboration with IBM … to develop an artificial intelligence software solution to support prostate cancer diagnostics and monitoring, utilizing MR imaging. This deal extends their earlier collaboration regarding liver cancer signed in January, 2018. IBM Imaging AI Marketplace Launched …
Kevin Conroy
Is Exact Sciences Stock a Buy? | 11/19/2019
… This month, Exact Sciences ( NASDAQ:EXAS ) finalized its purchase of Genomic Health, creating a formidable player in the realm of cancer diagnostics. Exact shelled out approximately $1.06 billion in cash and issued roughly 17.4 million … test. On its third-quarter conference call, Chairman and CEO Kevin Conroy spelled out its goal for Cologuard to “capture at least 40% of the U.S. colorectal screening market,” a significant increase from the current …
Scott Hutton
Biodesix Appoints Scott Hutton as Chief Executive Officer | Business Wire | 11/5/2019
… WIRE)–Nov 5, 2019– Biodesix, Inc. , the leader in lung cancer diagnostic solutions, today announced that current Chief Operating Officer Scott Hutton will become Chief Executive Officer on January 1, 2020. Current CEO David Brunel … the commercial operations for the Biodesix portfolio of leading lung cancer diagnostics, and the launch of the Nodify XL2™ test to improve the assessment of incidental lung nodules. Prior to Biodesix, Hutton was the Sr …
Sandra Horning
… paediatric patients living with GPA and MPA, two potentially life-threatening blood vessel disorders which are rare in children,” said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Today’s approval … the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and …
Chris Wicker
CSI Laboratories Announces New Line of Capital | Business Wire | 8/21/2019
… agreement with Bank of America for a revolving line of capital. “This credit facility gives CSI laboratories additional liquidity for new infrastructure and growth objectives, including the development of advanced testing initiatives,” said Chris Wicker, Chief Executive Officer of CSI. “It also provides additional financial assurances to our current and new customers that we will be able to quickly scale as needed to meet increased case load and turnaround time …
Janet Yellen
Fed, deal to form new US drug maker, and Trump’s intel chief resigns | CNBC | 7/29/2019
… Fed’s two-day July meeting, which begins tomorrow. Central bankers are expected to cut interest rates. Meanwhile, former Fed Chair Janet Yellen said she supports a 0.25% rate cut . (CNBC)The S&P 500 and … WATCH Genomic Health (GHDX) has agreed to be bought by cancer diagnostics firm Exact Sciences (EXAS). The companies are valuing the cash and stock transaction at $2.8 billion. Genomic Health shares were soaring in the …
Robert Lighthizer
Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know - TheStreet | 7/29/2019
… Meanwhile, trade negotiations between the U.S. and China will resume Tuesday in Shanghai. Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer will meet with a delegation led by China’s economy czar, Vice Premier Liu … Buy Genomic Health - Report Exact Sciences ( EXAS - Get Report ) , the cancer diagnostics company, is in advanced talks to buy healthcare company Genomic Health ( GHDX - Get Report ) for about $2.8 billion to bolster its cancer testing …
Robert Light
Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know - TheStreet | 7/29/2019
… Meanwhile, trade negotiations between the U.S. and China will resume Tuesday in Shanghai. Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer will meet with a delegation led by China’s economy czar, Vice Premier Liu … Buy Genomic Health - Report Exact Sciences ( EXAS - Get Report ) , the cancer diagnostics company, is in advanced talks to buy healthcare company Genomic Health ( GHDX - Get Report ) for about $2.8 billion to bolster its cancer testing …
Robert Li
Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know - TheStreet | 7/29/2019
… Meanwhile, trade negotiations between the U.S. and China will resume Tuesday in Shanghai. Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer will meet with a delegation led by China’s economy czar, Vice Premier Liu … Buy Genomic Health - Report Exact Sciences ( EXAS - Get Report ) , the cancer diagnostics company, is in advanced talks to buy healthcare company Genomic Health ( GHDX - Get Report ) for about $2.8 billion to bolster its cancer testing …
Satish Sanan
… 07:00 ET Source: Inspirata, Inc. Zürich, Switzerland, July 09, Experts consider artificial intelligence (AI) to be the next milestone in cancer diagnostics. AI-based methods are already more effective at detecting skin cancer than medical … expands the value we can bring to our clients”, states Satish Sanan, CEO of Inspirata. “Helping European cancer and medical centers to compress diagnosis-to-treatment-initiation intervals can improve patient survivability rates. Additionally, through …
Michael Kloss
… Michael Kloss, President and CEO of PHCHD said, “We are pleased to have completed this acquisition today and are excited to have added a leading global provider of solutions in the anatomical pathology industry to our group. Epredia brings a strong heritage in providing high-quality products and solutions that enable excellence in precision cancer diagnostics. It is a highly successful business that is already showing considerable growth and we …
Steven Silver
… disease. Including the challenging patients with intrathoracic (M0/M1a) disease resulted in a sensitivity of 90% (L858R), 83% (T790M) and 73% for exon 19 indels. “This a game-changer for liquid biopsies,” stated Steven Silverman, VP and General Manager of Bio-Techne’s Exosome Diagnostics brand. “The results from this validation study shows not only that our proprietary technique increases the performance of liquid biopsy mutation assays, but it can also …
Daniel Naimey
Worldwide Offices Epica International Appoints Daniel Naimey to VP of Market and Business Development Epica International Inc., the California-based advanced CT and robotics company, announces the appointment of Daniel Naimey to Vice President of … initiated Covidien’s move into non-invasive surgery systems for lung cancer diagnostics through the $350M acquisition of SuperDimension. Daniel initiated and developed subsequent acquisitions including Power Medical, Given Imaging, and Pnavel Systems. He possesses extensive …
State of Arizona
Investigating Breast Cancer: The Promise and Potential of Breast Cancer Vaccines | 6/30/2020
… we’re able to communicate with people. It’s tough on our patients. There’s no question. Chris Riback : Now, you work at Arizona State Biodesign Institute. I understand you do your clinical work at the Mayo Clinic … I predict and in turn, will end up impacting breast cancer diagnostics and care as we learn better how to sense nucleic acid in this case for corona viral nucleic acid. But I think that …
Investigating Breast Cancer: The Promise and Potential of Breast Cancer Vaccines | 6/30/2020
… we’re able to communicate with people. It’s tough on our patients. There’s no question. Chris Riback : Now, you work at Arizona State Biodesign Institute. I understand you do your clinical work at the Mayo Clinic … I predict and in turn, will end up impacting breast cancer diagnostics and care as we learn better how to sense nucleic acid in this case for corona viral nucleic acid. But I think that …
About:
Editor:
